Lyra Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $183 | $183 | $209 | $195 |
Gross Profit | -17 | 183 | 209 | 195 |
EBITDA | -7,235 | -8,415 | -9,615 | -9,599 |
EBIT | -7,435 | -8,543 | -9,766 | -9,638 |
Net Income | -7,437 | -8,547 | -10,979 | -11,873 |
Net Change In Cash | 183 | 183 | 209 | 195 |
Free Cash Flow | -6,610 | -8,842 | -11,294 | -16,274 |
Cash | 29,784 | 31,735 | 40,577 | 23,800 |
Basic Shares | 1,348 | 65,757 | 65,113 | 65,456 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $1,534 | $1,558 | $1,363 | $285 |
Gross Profit | 1,534 | 1,558 | 296 | 285 |
EBITDA | -60,262 | -65,250 | -53,923 | -42,614 |
EBIT | -60,733 | -65,528 | -54,990 | -43,615 |
Net Income | -93,435 | -62,680 | -55,278 | -42,410 |
Net Change In Cash | 1,534 | 1,558 | 1,363 | 285 |
Free Cash Flow | -72,349 | -64,351 | -43,549 | -29,205 |
Cash | 40,577 | 22,353 | 32,550 | 45,747 |
Basic Shares | 65,113 | 49,804 | 30,235 | 12,986 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | -$5.21 |
2025-03-31 | -$0.13 |
2024-12-31 | -$0.14 |
2024-09-30 | -$0.13 |
